Literature DB >> 2724434

Impotence evaluated by the use of prostaglandin E1.

T I Hwang1, C R Yang, S J Wang, C L Chang, T S Tzai, C H Chang, H C Wu.   

Abstract

We screened 80 patients at our hospital for the differential diagnosis of impotence using intracavernous injection of prostaglandin E1 (20 micrograms). The rate of positive response was 78.8 per cent (63 patients). Neither systemic reactions nor priapism occurred. However, a considerable incidence (23.8 per cent, 19 of 80 patients) of tolerable injection pain was encountered. The 133xenon penile washout study was conducted routinely in impotent men for hemodynamic evaluation of penile vascularity. In 80 patients a positive correlation between the response of intracavernous prostaglandin E1 injection and the result of the washout study was found (r equals 0.381, p less than 0.0002). We selected 14 subjects randomly to receive additional intravenous infusions of prostaglandin E1 (6 ampules, 120 micrograms total) for 3 days, after which another 133xenon washout study was done. The washout studies before and after intravenous prostaglandin E1 infusion were compared, and 10 patients (71.4 per cent) appeared to obtain improvement in half-time clearance and penile blood flow. However, only 3 patients noticed improvement subjectively. We suggest that prostaglandin E1 could be a desirable alternative for the diagnosis and treatment of impotence.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724434     DOI: 10.1016/s0022-5347(17)41306-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Intracavernous pharmacotherapy.

Authors:  M C Truss; A J Becker; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

2.  Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial?

Authors:  D J Thomas; V J Balaji; M J Coptcoat; G F Abercrombie
Journal:  J R Soc Med       Date:  1992-06       Impact factor: 5.344

3.  Gender differences in quality of life of patients with rectal cancer. A five-year prospective study.

Authors:  Christian E Schmidt; Beate Bestmann; Thomas Küchler; Walter E Longo; Volker Rohde; Bernd Kremer
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

Review 4.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

5.  Temporary prostatic stenting and androgen suppression: a new minimally invasive approach to malignant prostatic retention.

Authors:  K M Anson; D G Barnes; T P Briggs; G M Watson; R A Miller
Journal:  J R Soc Med       Date:  1993-11       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.